CMS Plans to Reduce Costs of Wegovy and Zepbound Enhancing Weight Loss Drug Access

Physicians at UVA Health specializing in diabetes and obesity are optimistic about improved access to weight loss medications following a recent announcement by the Centers for Medicare & Medicaid Services (CMS). CMS is set to reduce the costs of Wegovy and Zepbound for Medicare and Medicaid beneficiaries, potentially making these drugs more affordable for patients with coverage through these programs. The lower prices are expected to encourage wider adoption among commercial payers as they often align their coverage policies with CMS decisions. Originally approved for Type-2 diabetes treatment, Wegovy and Zepbound received FDA approval for obesity treatment five years ago. Despite this, access remains limited, with only seven state Medicaid programs currently covering anti-obesity medications and many imposing stringent eligibility requirements. For example, Virginia Medicaid requires patients to have a BMI of at least 37, even though the FDA recommends use for patients with a BMI starting at 27. Coverage among employer-based insurance plans varies significantly, with larger employers (those with over 1,000 employees) more likely to offer obesity medication benefits than small and medium-sized employers. Even when coverage exists, patients often face burdensome restrictions and administrative barriers that limit effective access. The physicians also highlight the prevalent stigma surrounding obesity treatment. They emphasize that obesity is driven by hormonal and neurochemical factors affecting appetite and fullness signals, not merely willpower. Weight loss medications like Wegovy and Zepbound work by correcting these biological mechanisms to support lifestyle changes. The anticipated cost reductions and increased coverage resulting from the CMS initiative could expand medication access for patients across Medicare, Medicaid, and commercial insurance plans. Broader accessibility may result in improved health outcomes through better obesity management, a key factor in reducing diabetes and other related chronic conditions.